From February 1, 2021 to March 31, 2021, the company has repurchased 2,899,300 shares, representing 0.51% for CNY 25.22 million. With this, the company has completed the repurchase of 2,899,300 shares, representing 0.51% for CNY 25.22 million under the buyback announced on February 2, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.85 CNY | -0.84% | -1.82% | +45.24% |
05-13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
04-25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+45.24% | 1.94B | |
+42.38% | 6.26B | |
-15.86% | 4.49B | |
+6.36% | 3.29B | |
-11.28% | 3.12B | |
-3.23% | 2.5B | |
-7.89% | 1.68B | |
-0.98% | 1.63B | |
-11.32% | 1.56B | |
+47.00% | 1.52B |
- Stock Market
- Equities
- 600285 Stock
- News Henan Lingrui Pharmaceutical Co., Ltd.
- Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.